Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Cerus Company

CERS
US1570851014
905249

Price

1.63
Today +/-
+0.02
Today %
+1.22 %
P

Cerus stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Cerus stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Cerus stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Cerus stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Cerus's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Cerus Stock Price History

DateCerus Price
10/24/20241.63 undefined
10/23/20241.61 undefined
10/22/20241.63 undefined
10/21/20241.68 undefined
10/18/20241.70 undefined
10/17/20241.63 undefined
10/16/20241.80 undefined
10/15/20241.80 undefined
10/14/20241.89 undefined
10/11/20241.82 undefined
10/10/20241.73 undefined
10/9/20241.87 undefined
10/8/20241.72 undefined
10/7/20241.72 undefined
10/4/20241.70 undefined
10/3/20241.68 undefined
10/2/20241.69 undefined
10/1/20241.70 undefined
9/30/20241.74 undefined
9/27/20241.75 undefined
9/26/20241.78 undefined
9/25/20241.77 undefined

Cerus Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Cerus, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Cerus from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Cerus’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Cerus. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Cerus’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Cerus’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Cerus’s growth potential.

Cerus Revenue, EBIT and net profit per share

DateCerus RevenueCerus EBITCerus Net Income
2026e217.52 M undefined3.63 M undefined-3.15 M undefined
2025e199.85 M undefined-5.43 M undefined-12.6 M undefined
2024e180.22 M undefined-17.26 M undefined-24.57 M undefined
2023186.8 M undefined-26.33 M undefined-37.49 M undefined
2022188.3 M undefined-33.8 M undefined-42.8 M undefined
2021159.5 M undefined-48.6 M undefined-54.4 M undefined
2020114.2 M undefined-58.3 M undefined-59.9 M undefined
201993.8 M undefined-66.2 M undefined-71.2 M undefined
201876.1 M undefined-55 M undefined-57.6 M undefined
201751.3 M undefined-57.5 M undefined-60.6 M undefined
201639.3 M undefined-61.2 M undefined-62.9 M undefined
201534.2 M undefined-61.1 M undefined-55.9 M undefined
201436.4 M undefined-44.5 M undefined-38.8 M undefined
201339.7 M undefined-28.3 M undefined-43.3 M undefined
201236.8 M undefined-17.3 M undefined-15.9 M undefined
201133 M undefined-15.9 M undefined-17 M undefined
201023.1 M undefined-15.8 M undefined-16.9 M undefined
200918 M undefined-22.8 M undefined-24.1 M undefined
200816.5 M undefined-30.5 M undefined-29.2 M undefined
200711 M undefined-33.7 M undefined-45.3 M undefined
200630.3 M undefined-2.3 M undefined-4.8 M undefined
200513.5 M undefined-8 M undefined13.1 M undefined
200413.9 M undefined-23.9 M undefined-31.2 M undefined

Cerus Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
00463622148913133011161823333639363439517693114159188186180199217
---50.00-50.00100.00-66.67--50.00300.00100.0012.5044.44-130.77-63.3345.4512.5027.7843.489.098.33-7.69-5.5614.7130.7749.0222.3722.5839.4718.24-1.06-3.2310.569.05
------------100.00100.0093.3345.4537.5027.7847.8342.4244.4443.5941.6729.4148.7254.9057.8964.5264.0460.3860.1162.37---
000000000000131328565111416171510192844607396113116000
-2-3-2-2-10-15-30-24-40-53-59-53-23-8-2-33-30-22-15-15-17-28-44-61-61-57-55-66-58-48-33-26-17-53
---50.00-33.33-333.33-250.00-1,500.00-1,200.00-4,000.00-1,325.00-737.50-588.89-176.92-61.54-6.67-300.00-187.50-122.22-65.22-45.45-47.22-71.79-122.22-179.41-156.41-111.76-72.37-70.97-50.88-30.19-17.55-13.98-9.44-2.511.38
-2-3-1-2-10-14-29-22-36-49-57-58-3113-4-45-29-24-16-17-15-43-38-55-62-60-57-71-59-54-42-37-24-12-3
-50.00-66.67100.00400.0040.00107.14-24.1463.6436.1116.331.75-46.55-141.94-130.771,025.00-35.56-17.24-33.336.25-11.76186.67-11.6344.7412.73-3.23-5.0024.56-16.90-8.47-22.22-11.90-35.14-50.00-75.00
6.26.26.26.26.68.49.311.113.115.115.819.422.12428.631.932.434.840.348.154.567.674.896.1101.8108.2131.7139.8163.9171.3176.5180.27000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Cerus Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Cerus is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                           
7.89.7621.619.840.490.3123.564.311095.345.893.456.922.619.93025.826.757.751.3107.971.660.7117.683.3133.6129.4102.265.85
00000000000007.87.23.64.86.14.46.15.55.86.912.48.816.921.225.134.435.5
000000000000000000000000000000
0000000000001.87.111.17.766.410.213.11510.812.514.513.519.523.326.82939.87
0.30.30.54.60.30.20.81.62.95.74.55.27.52.21.21.111.42.61.23.163.12.378.45.45.84.63.22
8.1106.526.220.140.691.1125.167.2115.799.851102.77442.132.341.839.743.978.174.9130.594.189.9146.9128.1183.5187.1170.2144.44
1.41.31.210.71335.52.60.91.21.61.31.81.22.421.72.23.83.532.18.1292725.223.519.35
00000000001.26.211.21.92.3000000000000000
000000000000000000000000000000
000000000000000021.71.51.31.10.90.70.50.30.10000
00000000000000001.31.31.31.31.31.31.31.31.31.31.31.31.31.32
0.20.21.10.10.10.10.10.20.20.20.10.20.31.11.10.90.80.50.40.40.73.24.34.46.879.723.923.232.64
1.61.52.31.10.81.13.13.25.72.82.27.613.14.35.22.16.55.54.95.26.98.99.38.316.537.43850.44853.31
9.711.58.827.320.941.794.2128.372.9118.510258.6115.878.347.334.448.345.248.883.381.8139.4103.498.2163.4165.5221.5237.5218.2197.75
                                                           
000009.59.59.59.59.59.59.59.59.59.59.59.59.60.10.10.10.10.10.10.10.10.20.20.20.18
0.010.020.030.060.060.110.190.270.280.330.330.330.40.410.410.420.440.450.480.550.580.690.720.760.860.911.011.051.081.1
-7.6-10-20.2-34.9-64.4-87.5-123.7-173.1-230.3-288.6-319.7-306.6-311.4-356.7-385.9-410-427-443.9-459.9-503.2-541.9-597.8-660.7-721.3-778.9-850.1-910-964.3-1,007.1-1,044.61
0000000000-0.3-0.300.10.20.10.100007.30.1-0.1-0.30.10.7-0.1-2.8-1.27
000000000000000000000000000000
5.58.74.822.4-3.62876.9106.756.152.521.535.310159.934.221.523.618.419.142.841.694.857.838.984.457103.884.767.652.65
0.50.30.41.314.126.18.210.64.61.52.16.710.184.43.24.77.25.79.95.28.61118.622.224.235.63323.84
0.80.42.43.45.56.26.17.25.44.84.85.27.52.20.61.165.87.69.88.49.910.711.219.822.626.727.627.321.68
0.91.91000.500.90.70.635.311.10.61.50.43.18.78.1620.610.93.80.70.96.40.60.60.70.62
00000000055.834.54.804.53.94.300000000000000
0.10.10.10.100000000.10.10001.82.54.83.4036.907.958.514.756.220
2.32.73.94.819.68.712.216.316.765.876.123.314.918.312.912.919.721.125.639.529.221.926.923.152.750.46078.6117.167.52
0.100.1055.15.15.1004.50.100003.14.72.909.916.812.429.82239.439.654.713.659.8
0000000000000000001001001001002000000000
1.900000000000000.20.11.61.21.21.11.15.86.26.44.318.71818.618.816.99
200.1055.15.15.1004.50.1000.20.14.75.94.21.211.122.718.836.226.358.157.673.332.476.78
4.32.744.824.613.817.321.416.765.880.623.414.918.313.11324.42729.840.740.344.645.759.379108.5117.6151.9149.5144.3
9.811.48.827.22141.894.2128.172.8118.3102.158.7115.978.247.334.54845.448.983.581.9139.4103.598.2163.4165.5221.4236.6217.1196.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Cerus provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Cerus's financial health and stability.

Assets

Cerus's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Cerus must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Cerus after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Cerus's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-3-1-2-10-14-29-22-36-49-57-58-3113-4-45-29-24-16-16-15-43-38-55-62-60-57-71-59-54-42-37
0000000012320000000001111123322
0000000000000000000000000000000
5-1-10-219-10330-315-6-3-4-75000-2030-313-12-3-9-15-31
000000000000-21-7124433321261619222837505444
0000000000000000001000112233459
0000000000000000000000000000000
1,000-2,000-3,000-8,000-16,000-9,000-33,000-32,000-44,000-55,000-58,000-12,000-14,000-14,000-37,000-34,000-14,000-14,000-15,000-13,000-26,000-39,000-51,000-53,000-52,000-31,000-65,000-40,000-33,000-25,000-43,000
0000000-2-1-5000-10-10-1000-2000-1-8-10-2-4
0000-10-3-2315-4112-452815-79239000-29-31-190-4328-491288
0000-9-3-2318-4017-442916-69249100-28-12-190-4237-47131013
0000000000000000000000000000000
2000000000490-34-4000620-46901001332109
2556328548578154006711121991463308825329230881230
455532854847811040-33631112261114583697244392439134410
00000000000000000000000000001,00000
0000000000000000000000000000000
511-35-5-268-7-42016-3340-26-9611-312-648-48-8175112-13-23
1.42-3.81-3.54-9.1-17.01-10.05-34.01-34.65-45.24-60.68-58.92-13.32-15.81-15.8-38-35.27-14.74-15.96-15.79-14-27.32-41.92-51.85-54.09-52.59-32.39-74.78-42.36-34.83-27.62-47.77
0000000000000000000000000000000

Cerus stock margins

The Cerus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Cerus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Cerus.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Cerus's sales revenue. A higher gross margin percentage indicates that the Cerus retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Cerus's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Cerus's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Cerus's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Cerus. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Cerus's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Cerus Margin History

Cerus Gross marginCerus Profit marginCerus EBIT marginCerus Profit margin
2026e62.54 %1.67 %-1.45 %
2025e62.54 %-2.72 %-6.31 %
2024e62.54 %-9.58 %-13.63 %
202362.54 %-14.09 %-20.07 %
202260.22 %-17.95 %-22.73 %
202160.19 %-30.47 %-34.11 %
202064.01 %-51.05 %-52.45 %
201964.39 %-70.58 %-75.91 %
201858.34 %-72.27 %-75.69 %
201756.14 %-112.09 %-118.13 %
201648.35 %-155.73 %-160.05 %
201531.58 %-178.65 %-163.45 %
201441.76 %-122.25 %-106.59 %
201343.07 %-71.28 %-109.07 %
201244.02 %-47.01 %-43.21 %
201143.94 %-48.18 %-51.52 %
201048.05 %-68.4 %-73.16 %
200930 %-126.67 %-133.89 %
200841.21 %-184.85 %-176.97 %
200752.73 %-306.36 %-411.82 %
200695.05 %-7.59 %-15.84 %
2005100 %-59.26 %97.04 %
2004100 %-171.94 %-224.46 %

Cerus Stock Sales Revenue, EBIT, Earnings per Share

The Cerus earnings per share therefore indicates how much revenue Cerus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cerus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cerus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cerus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cerus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Cerus Revenue, EBIT and net profit per share

DateCerus Sales per ShareCerus EBIT per shareCerus Earnings per Share
2026e1.17 undefined0 undefined-0.02 undefined
2025e1.08 undefined0 undefined-0.07 undefined
2024e0.97 undefined0 undefined-0.13 undefined
20231.04 undefined-0.15 undefined-0.21 undefined
20221.07 undefined-0.19 undefined-0.24 undefined
20210.93 undefined-0.28 undefined-0.32 undefined
20200.7 undefined-0.36 undefined-0.37 undefined
20190.67 undefined-0.47 undefined-0.51 undefined
20180.58 undefined-0.42 undefined-0.44 undefined
20170.47 undefined-0.53 undefined-0.56 undefined
20160.39 undefined-0.6 undefined-0.62 undefined
20150.36 undefined-0.64 undefined-0.58 undefined
20140.49 undefined-0.59 undefined-0.52 undefined
20130.59 undefined-0.42 undefined-0.64 undefined
20120.68 undefined-0.32 undefined-0.29 undefined
20110.69 undefined-0.33 undefined-0.35 undefined
20100.57 undefined-0.39 undefined-0.42 undefined
20090.52 undefined-0.66 undefined-0.69 undefined
20080.51 undefined-0.94 undefined-0.9 undefined
20070.34 undefined-1.06 undefined-1.42 undefined
20061.06 undefined-0.08 undefined-0.17 undefined
20050.56 undefined-0.33 undefined0.55 undefined
20040.63 undefined-1.08 undefined-1.41 undefined

Cerus business model

Cerus Corporation is a biotechnology company specialized in the development and marketing of products for the processing and transfusion of blood products. The company was founded in 1991 and is headquartered in Concord, California. Cerus Corporation is listed on the NASDAQ stock exchange and employs approximately 450 employees worldwide. The history of Cerus Corporation began when its founder, Stephen Isaacs, received a blood transfusion and subsequently became infected with the Hepatitis B virus. This incident inspired him to start a company focusing on the development of technologies for the safe transfusion of blood products. In 1993, Cerus Corporation introduced its first product, the Intercept Blood System. This system utilized ultraviolet light and chemicals to deactivate pathogens such as viruses, bacteria, and parasites in blood. The business model of Cerus Corporation revolves around the development and distribution of products for medical needs. The company's focus is on the processing of blood products such as platelets, plasma, and red blood cells to reduce the risk of infectious diseases and other potentially harmful side effects in blood transfusions. Cerus also provides training and technical support for its products. Cerus Corporation has several divisions, including the Intercept Blood System, Blood Center Technology, and Innovative Technology. The Intercept Blood System division is the largest and most popular, offering products such as the Intercept Blood System for platelets and plasma, the Intercept Blood System for red blood cells, the Intercept Blood System for PAS (reduced volume blood bank) and the Intercept Blood System for Fresh Frozen Plasma. Cerus Corporation's Blood Center Technology division provides technologies and devices for blood banks and transfusion services, including transfusion safety systems and blood testing devices. The Innovative Technology division specializes in the development of new technologies and products. Another product of Cerus Corporation is INTERCEPT FDA Approved Plasma, which was approved by the US Food and Drug Administration (FDA) in 2018. The plasma is made from donated blood and processed using the INTERCEPT technology. The INTERCEPT technology decontaminates various blood components, increasing their safety in transfusions. Cerus Corporation has achieved significant success in the medical technology industry. Cerus Corporation's Intercept Blood System is approved in more than 25 countries and has helped save countless lives and prevent diseases for healthcare professionals and patients. The company has been recognized multiple times for its innovative products and services, including receiving the Gold Medal at the Edison Awards in 2017 and the Technology Pioneer Award from the World Economic Forum in 2016. In summary, Cerus Corporation is a successful biotechnology company that develops and distributes innovative technologies for the processing and transfusion of blood products. Through its technology and products, Cerus contributes to increasing the safety of blood transfusions by reducing the risk of infectious diseases and other potentially dangerous side effects. Cerus Corporation will continue to play an important role in the medical technology industry in the future. Cerus is one of the most popular companies on Eulerpool.com.

Cerus Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Cerus Revenue by Segment

Segmente20222021202020192018
Product162.05 M USD130.86 M USD91.92 M USD74.65 M USD60.91 M USD
Government Contract26.27 M USD28.66 M USD22.33 M USD19.13 M USD15.14 M USD

Cerus Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Cerus Revenue by Segment

DateBELGIUMCommonwealth of Independent States CountriesEurope, middle east and africaFRANCEKUWAITNorth AmericaOther countriesOther CountriesSPAINSWITZERLANDUnited States
20186.79 M USD-46.97 M USD23.04 M USD883,000 USD12.7 M USD17.63 M USD1.24 M USD--15.14 M USD
20155.73 M USD3.36 M USD-7.73 M USD---10.39 M USD4.07 M USD2.94 M USD-

Cerus SWOT Analysis

Strengths

Cerus Corp has innovative technology that allows for safer blood transfusions, reducing the risk of transfusion-transmitted infections.

The company has established partnerships with major blood centers and hospitals, providing a strong distribution network.

Cerus Corp's products have gained regulatory approvals in multiple countries, indicating their adherence to global quality standards.

Weaknesses

Cerus Corp is heavily dependent on its flagship product, the INTERCEPT Blood System, which generates a significant portion of its revenue. Any disruption in production or supply chain issues could have a detrimental impact on the company.

The company faces intense competition from other blood safety technology providers, which could potentially limit market share and profitability.

Opportunities

With an increasing focus on patient safety and infection prevention, there is a growing demand for blood safety solutions, providing Cerus Corp with opportunities for market expansion.

The company can explore strategic partnerships or acquisitions to enhance its product portfolio and diversify its revenue streams.

Threats

Changes in regulations or standards related to blood safety could pose challenges for Cerus Corp and require significant modifications to its products and processes.

Economic downturns or changes in healthcare spending patterns may impact the affordability and demand for Cerus Corp's products.

Cerus Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Cerus historical P/E ratio, EBIT multiple, and P/S ratio

Cerus shares outstanding

The number of shares was Cerus in 2023 — This indicates how many shares 180.27 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Cerus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Cerus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Cerus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Cerus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Cerus.

Cerus latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.04 -0.03  (26.47 %)2024 Q2
3/31/2024-0.05 -0.05  (-5.04 %)2024 Q1
12/31/2023-0.02 -0.01  (59.18 %)2023 Q4
9/30/2023-0.05 -0.03  (44.03 %)2023 Q3
6/30/2023-0.06 -0.06  (-5.08 %)2023 Q2
3/31/2023-0.08 -0.09  (-17.65 %)2023 Q1
12/31/2022-0.05 -0.08  (-64.95 %)2022 Q4
9/30/2022-0.06 -0.05  (12.43 %)2022 Q3
6/30/2022-0.07 -0.05  (27.95 %)2022 Q2
3/31/2022-0.09 -0.07  (20.18 %)2022 Q1
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Cerus stock

Eulerpool World ESG Rating (EESG©)

38/ 100

🌱 Environment

15

👫 Social

29

🏛️ Governance

69

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees61
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees53
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Cerus shareholders

%
Name
Stocks
Change
Date
11.62720 % ARK Investment Management LLC21,545,196630,8703/31/2024
10.51125 % Baker Bros. Advisors LP19,477,339395,32712/31/2023
6.56447 % BlackRock Institutional Trust Company, N.A.12,163,963310,73512/31/2023
5.32686 % The Vanguard Group, Inc.9,870,671148,78612/31/2023
4.64814 % PRIMECAP Management Company8,613,000012/31/2023
4.18278 % Nikko Asset Management Co., Ltd.7,750,700182,6293/31/2024
3.55306 % Senvest Management, LLC6,583,826-675,00012/31/2023
3.39131 % Wasatch Global Investors Inc6,284,104-245,9153/31/2024
2.16553 % Geode Capital Management, L.L.C.4,012,720242,92312/31/2023
1.89802 % State Street Global Advisors (US)3,517,032-1,443,01112/31/2023
1
2
3
4
5
...
10

Cerus Executives and Management Board

Mr. William Greenman56
Cerus President, Chief Executive Officer, Director (since 2006)
Compensation 5.26 M
Mr. Vivek Jayaraman48
Cerus Chief Operating Officer
Compensation 2.49 M
Mr. Kevin Green51
Cerus Chief Financial Officer, Vice President - Finance
Compensation 2.01 M
Dr. Laurence Corash79
Cerus Chief Scientific Officer (since 1996)
Compensation 1.72 M
Dr. Richard Benjamin63
Cerus Chief Medical Officer
Compensation 1.67 M
1
2
3
4

Most common questions regarding Cerus

What values and corporate philosophy does Cerus represent?

Cerus Corp represents a commitment to ensuring the safety of the global blood supply. With a strong corporate philosophy focused on innovation and collaboration, Cerus Corp strives to provide innovative solutions to enhance transfusion medicine. The company's values revolve around patient-centricity, quality, and integrity, ensuring the highest standards in product development and commercialization. By leveraging their cutting-edge technologies like the INTERCEPT Blood System, Cerus Corp aims to prevent the risk of transfusion-transmitted infections and improve patient outcomes. Through their dedication to safety and pioneering advancements, Cerus Corp continues to play a vital role in protecting lives through safer blood transfusions.

In which countries and regions is Cerus primarily present?

Cerus Corp, a leading healthcare company, primarily operates in various countries and regions worldwide. With a global presence, the company's main operations can be found in North America, including the United States and Canada, where it is headquartered. Furthermore, Cerus Corp has an established footprint in Europe, particularly in countries like Germany, France, and the United Kingdom. Additionally, the company extends its reach to the Asia-Pacific region, encompassing countries such as Japan and Australia. Cerus Corp's international presence showcases its commitment to providing innovative solutions and services in transfusion medicine and blood safety on a global scale.

What significant milestones has the company Cerus achieved?

Cerus Corp has achieved several significant milestones. The company's Intercept Blood System has received regulatory approvals in key markets, including the United States and Europe. This innovative technology has revolutionized blood safety by reducing the risk of transfusion-transmitted infections. Cerus Corp has also established successful collaborations with leading organizations, securing partnerships and licensing agreements to expand its market presence. Moreover, the company has conducted extensive clinical trials, demonstrating the safety and efficacy of its products. With a strong commitment to advancing medical advancements, Cerus Corp continues to make remarkable strides in improving the safety and availability of blood products worldwide.

What is the history and background of the company Cerus?

Cerus Corp is a medical device company founded in 1991. It specializes in developing and commercializing blood transfusion safety systems. With its flagship product, the INTERCEPT Blood System, Cerus Corp is dedicated to preventing the transmission of infectious diseases through blood transfusions. The innovative technology of the INTERCEPT Blood System helps in reducing the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. Cerus Corp has established collaborations with various blood centers and organizations worldwide to implement their solution and safeguard the blood supply. This California-based company continues to strive towards ensuring safer transfusions for patients globally.

Who are the main competitors of Cerus in the market?

The main competitors of Cerus Corp in the market include companies such as Grifols S.A., Baxter International Inc., and Terumo Corporation.

In which industries is Cerus primarily active?

Cerus Corp is primarily active in the healthcare industry.

What is the business model of Cerus?

The business model of Cerus Corp revolves around developing and commercializing innovative systems for blood transfusion safety. Cerus Corp primarily focuses on the production of INTERCEPT Blood System, which is designed to minimize the risk of transfusion-transmitted infections. By providing pathogen inactivation technology, Cerus Corp ensures the safety and effectiveness of blood components for patients in need. With a commitment to improving global blood safety, Cerus Corp collaborates with blood centers, hospitals, and other healthcare institutions to implement their groundbreaking technology. Through its proactive approach, Cerus Corp aims to enhance the overall quality and access to safe blood transfusions worldwide.

What is the P/E ratio of Cerus 2024?

The Cerus P/E ratio is -11.96.

What is the P/S ratio of Cerus 2024?

The Cerus P/S ratio is 1.63.

What is the Quality Investing of Cerus?

The Quality Investing for Cerus is 4/10.

What is the revenue of Cerus 2024?

The expected Cerus revenue is 180.22 M USD.

How high is the profit of Cerus 2024?

The expected Cerus profit is -24.57 M USD.

What is the business model of Cerus

Cerus Corporation is a biomedical company specializing in the development and commercialization of products for virus inactivation and blood transfusion safety, as well as devices for plasmapheresis. The company was founded in 1991 and is headquartered in Concord, California, USA.

What is the Cerus dividend?

Cerus pays a dividend of 0 USD distributed over payouts per year.

How often does Cerus pay dividends?

The dividend cannot currently be calculated for Cerus or the company does not pay out a dividend.

What is the Cerus ISIN?

The ISIN of Cerus is US1570851014.

What is the Cerus WKN?

The WKN of Cerus is 905249.

What is the Cerus ticker?

The ticker of Cerus is CERS.

How much dividend does Cerus pay?

Over the past 12 months, Cerus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cerus is expected to pay a dividend of 0 USD.

What is the dividend yield of Cerus?

The current dividend yield of Cerus is .

When does Cerus pay dividends?

Cerus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cerus?

Cerus paid dividends every year for the past 0 years.

What is the dividend of Cerus?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cerus located?

Cerus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cerus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cerus from 10/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/24/2024.

When did Cerus pay the last dividend?

The last dividend was paid out on 10/24/2024.

What was the dividend of Cerus in the year 2023?

In the year 2023, Cerus distributed 0 USD as dividends.

In which currency does Cerus pay out the dividend?

The dividends of Cerus are distributed in USD.

All fundamentals about Cerus

Our stock analysis for Cerus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cerus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.